Golgi fragmentation – One of the earliest organelle phenotypes in Alzheimer’s disease neurons

Alzheimer’s disease (AD) is the most common cause of dementia, with no current cure. Consequently, alternative approaches focusing on early pathological events in specific neuronal populations, besides targeting the well-studied amyloid beta (Aβ) accumulations and Tau tangles, are needed. In this study, we have investigated disease phenotypes specific to glutamatergic forebrain neurons and mapped the timeline of their occurrence, by implementing familial and sporadic human induced pluripotent stem cell models as well as the 5xFAD mouse model. We recapitulated characteristic late AD phenotypes, such as increased Aβ secretion and Tau hyperphosphorylation, as well as previously well documented mitochondrial and synaptic deficits. Intriguingly, we identified Golgi fragmentation as one of the earliest AD phenotypes, indicating potential impairments in protein processing and post-translational modifications. Computational analysis of RNA sequencing data revealed differentially expressed genes involved in glycosylation and glycan patterns, whilst total glycan profiling revealed minor glycosylation differences. This indicates general robustness of glycosylation besides the observed fragmented morphology. Importantly, we identified that genetic variants in Sortilin-related receptor 1 (SORL1) associated with AD could aggravate the Golgi fragmentation and subsequent glycosylation changes. In summary, we identified Golgi fragmentation as one of the earliest disease phenotypes in AD neurons in various in vivo and in vitro complementary disease models, which can be exacerbated via additional risk variants in SORL1. Graphical Abstract

[1]  Nadezhda T. Doncheva,et al.  The transcriptomic landscape of neurons carrying PSEN1 mutations reveals changes in extracellular matrix components and non-coding gene expression , 2022, Neurobiology of Disease.

[2]  H. Wandall,et al.  In-Depth Profiling of O-Glycan Isomers in Human Cells Using C18 Nanoliquid Chromatography–Mass Spectrometry and Glycogenomics , 2022, Analytical chemistry.

[3]  A. Wingo,et al.  Large‐scale deep multi‐layer analysis of Alzheimer’s disease brain reveals strong proteomic disease‐related changes not observed at the RNA level , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[4]  D. Campion,et al.  Impaired SorLA maturation and trafficking as a new mechanism for SORL1 missense variants in Alzheimer disease , 2021, Acta Neuropathologica Communications.

[5]  H. Tanila,et al.  Hippocampal disruptions of synaptic and astrocyte metabolism are primary events of early amyloid pathology in the 5xFAD mouse model of Alzheimer’s disease , 2021, Cell Death & Disease.

[6]  A. Wingo,et al.  Large-scale deep multi-layer analysis of Alzheimer’s disease brain reveals strong proteomic disease-related changes not observed at the RNA level , 2021, Nature Neuroscience.

[7]  C. Mannella,et al.  Effect of crista morphology on mitochondrial ATP output: A computational study , 2021, Current research in physiology.

[8]  K. Freude,et al.  Implications of Glycosylation in Alzheimer’s Disease , 2021, Frontiers in Neuroscience.

[9]  A. Mahadevan,et al.  Alteration in synaptic nanoscale organization dictates amyloidogenic processing in Alzheimer's disease , 2020, iScience.

[10]  Hui Peng,et al.  Identification of SCARA3 with potential roles in metabolic disorders , 2020, Aging.

[11]  E. Gazit,et al.  Differential effects of putative N-glycosylation sites in human Tau on Alzheimer’s disease-related neurodegeneration , 2020, Cellular and Molecular Life Sciences.

[12]  J. Sibarita,et al.  Real-time nanoscale organization of amyloid precursor protein. , 2020, Nanoscale.

[13]  R. Tanzi,et al.  Amyloid-β42/40 ratio drives tau pathology in 3D human neural cell culture models of Alzheimer’s disease , 2020, Nature Communications.

[14]  Michael J MacCoss,et al.  Skyline for Small Molecules: A Unifying Software Package for Quantitative Metabolomics. , 2020, Journal of proteome research.

[15]  Oliver C. Grant,et al.  O-glycosylation on cerebrospinal fluid and plasma Apolipoprotein E differs in the lipid binding domain. , 2019, Glycobiology.

[16]  Pei-Pei Liu,et al.  History and progress of hypotheses and clinical trials for Alzheimer’s disease , 2019, Signal Transduction and Targeted Therapy.

[17]  M. Larsen,et al.  Perturbations in RhoA signalling cause altered migration and impaired neuritogenesis in human iPSC-derived neural cells with PARK2 mutation , 2019, Neurobiology of Disease.

[18]  E. Martínez-Alonso,et al.  Golgi Fragmentation in Neurodegenerative Diseases: Is There a Common Cause? , 2019, Cells.

[19]  Erpan Ahat,et al.  Golgi Structure and Function in Health, Stress, and Diseases , 2019, Results and problems in cell differentiation.

[20]  M. Filius,et al.  Highly sensitive CE-ESI-MS analysis of N-glycans from complex biological samples , 2019, Nature Communications.

[21]  Ravi S Muddashetty,et al.  Generation of two iPSC lines with either a heterozygous V717I or a heterozygous KM670/671NL mutation in the APP gene. , 2019, Stem cell research.

[22]  P. Gleeson,et al.  The trans-Golgi network is a major site for α-secretase processing of amyloid precursor protein in primary neurons , 2018, The Journal of Biological Chemistry.

[23]  Mark Gerstein,et al.  GENCODE reference annotation for the human and mouse genomes , 2018, Nucleic Acids Res..

[24]  P. Alifragis,et al.  Synaptic dysfunction in Alzheimer's disease: the effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention , 2018, Neural regeneration research.

[25]  N. Taniguchi,et al.  N-glycan and Alzheimer's disease. , 2017, Biochimica et biophysica acta. General subjects.

[26]  A. Larsen,et al.  Sortilin-Related Receptor Expression in Human Neural Stem Cells Derived from Alzheimer's Disease Patients Carrying the APOE Epsilon 4 Allele , 2017, Neural plasticity.

[27]  Jordan A. Ramilowski,et al.  An atlas of human long non-coding RNAs with accurate 5′ ends , 2017, Nature.

[28]  J. DeFelipe,et al.  Morphometric alterations of Golgi apparatus in Alzheimer's disease are related to tau hyperphosphorylation , 2017, Neurobiology of Disease.

[29]  Yigong Shi,et al.  Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Aβ42 and Aβ40 peptides by γ-secretase , 2016, Proceedings of the National Academy of Sciences.

[30]  W. M. van der Flier,et al.  Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer’s Disease in a Family with Several Generations of APOE-ɛ4 Homozygosity , 2016, Journal of Alzheimer's disease : JAD.

[31]  T. Nielsen,et al.  Generation of a gene-corrected isogenic control hiPSC line derived from a familial Alzheimer's disease patient carrying a L150P mutation in presenilin 1. , 2016, Stem cell research.

[32]  Stefan J. Kempf,et al.  Neurofibrillary tangles in Alzheimer's disease: elucidation of the molecular mechanism by immunohistochemistry and tau protein phospho-proteomics , 2016, Neural regeneration research.

[33]  G. Waldemar,et al.  Generation of a gene-corrected isogenic control cell line from an Alzheimer's disease patient iPSC line carrying a A79V mutation in PSEN1. , 2016, Stem cell research.

[34]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[35]  G. Waldemar,et al.  Generation of induced pluripotent stem cells (iPSCs) from an Alzheimer's disease patient carrying an A79V mutation in PSEN1. , 2016, Stem cell research.

[36]  M. Bekier,et al.  Golgi fragmentation in Alzheimer's disease , 2015, Front. Neurosci..

[37]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[38]  C. Cotman,et al.  Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimer's disease , 2014, Neurobiology of Aging.

[39]  Z. Tümer,et al.  Transient p53 Suppression Increases Reprogramming of Human Fibroblasts without Affecting Apoptosis and DNA Damage , 2014, Stem cell reports.

[40]  L. Tan,et al.  The Role of SORL1 in Alzheimer’s Disease , 2014, Molecular Neurobiology.

[41]  Yanzhuang Wang,et al.  Aβ-induced Golgi fragmentation in Alzheimer’s disease enhances Aβ production , 2014, Proceedings of the National Academy of Sciences.

[42]  J. Ávila,et al.  Deconstructing Mitochondrial Dysfunction in Alzheimer Disease , 2013, Oxidative medicine and cellular longevity.

[43]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[44]  T. Lehtimäki,et al.  Genetic Loci Associated with Alzheimer’s Disease and Cerebrospinal Fluid Biomarkers in a Finnish Case-Control Cohort , 2013, PloS one.

[45]  Pelin Yilmaz,et al.  The SILVA ribosomal RNA gene database project: improved data processing and web-based tools , 2012, Nucleic Acids Res..

[46]  Rene Ranzinger,et al.  The GlycanBuilder and GlycoWorkbench glycoinformatics tools: updates and new developments , 2012, Biological chemistry.

[47]  F. J. Livesey,et al.  Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks , 2012, Nature Protocols.

[48]  Wei Li,et al.  RSeQC: quality control of RNA-seq experiments , 2012, Bioinform..

[49]  B. Lu,et al.  Synapses and Dendritic Spines as Pathogenic Targets in Alzheimer's Disease , 2012, Neural plasticity.

[50]  J. Nyengaard,et al.  Retromer Binds the FANSHY Sorting Motif in SorLA to Regulate Amyloid Precursor Protein Sorting and Processing , 2012, The Journal of Neuroscience.

[51]  Marcel Martin Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[52]  André M Deelder,et al.  Cotton HILIC SPE microtips for microscale purification and enrichment of glycans and glycopeptides. , 2011, Analytical chemistry.

[53]  S. Faraone,et al.  Review Article: Genetics of Alzheimer Disease , 2010, Journal of geriatric psychiatry and neurology.

[54]  A. Kakita,et al.  Increased Levels of Soluble LR11 in Cerebrospinal Fluid of Patients with Alzheimer Disease , 2010, Dementia and Geriatric Cognitive Disorders.

[55]  A. Levey,et al.  Loss of LR11/SORLA Enhances Early Pathology in a Mouse Model of Amyloidosis: Evidence for a Proximal Role in Alzheimer's Disease , 2008, The Journal of Neuroscience.

[56]  M. Molinari,et al.  Consequences of individual N-glycan deletions and of proteasomal inhibition on secretion of active BACE. , 2008, Molecular biology of the cell.

[57]  M. Pool,et al.  NeuriteTracer: A novel ImageJ plugin for automated quantification of neurite outgrowth , 2008, Journal of Neuroscience Methods.

[58]  A. Fagan,et al.  Extreme cerebrospinal fluid amyloid β levels identify family with late‐onset Alzheimer's disease presenilin 1 mutation , 2007, Annals of neurology.

[59]  K. Lunetta,et al.  The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease , 2007, Nature Genetics.

[60]  C. van Broeckhoven,et al.  Mean age‐of‐onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Aβ42 and decreased Aβ40 , 2006, Human mutation.

[61]  Hirohisa Tajima,et al.  Neuronal cell death in Alzheimer's disease and a neuroprotective factor, humanin. , 2006, Current neuropharmacology.

[62]  Theo Wallimann,et al.  Mitochondrial creatine kinase in human health and disease. , 2006, Biochimica et biophysica acta.

[63]  Irwin D Kuntz,et al.  Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[64]  B. Hyman,et al.  Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[65]  Robert S. Balaban,et al.  Mitochondria, Oxidants, and Aging , 2005, Cell.

[66]  I. Grundke‐Iqbal,et al.  Tau pathology in Alzheimer disease and other tauopathies. , 2005, Biochimica et biophysica acta.

[67]  P. Greengard,et al.  Presenilin-1 Regulates Intracellular Trafficking and Cell Surface Delivery of β-Amyloid Precursor Protein* , 2003, The Journal of Biological Chemistry.

[68]  M. Farquhar,et al.  Cell type-dependent variations in the subcellular distribution of alpha- mannosidase I and II , 1993, The Journal of cell biology.

[69]  E. Reynolds THE USE OF LEAD CITRATE AT HIGH pH AS AN ELECTRON-OPAQUE STAIN IN ELECTRON MICROSCOPY , 1963, The Journal of cell biology.

[70]  OUP accepted manuscript , 2021, Nucleic Acids Research.

[71]  G. Waldemar,et al.  Lab resource: Stem cell lineGeneration of induced pluripotent stem cells (iPSCs) from an Alzheimer's disease patient carrying a L150P mutation in PSEN-1 , 2016 .

[72]  N. Taniguchi,et al.  Bisecting GlcNAc modification stabilizes BACE1 protein under oxidative stress conditions. , 2016, The Biochemical journal.

[73]  Stavros J. Baloyannis Golgi apparatus and protein trafficking in Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.

[74]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[75]  A. Deelder,et al.  HILIC SPE microtips for micro-scale purification and enrichment of glycans and glycopeptides , 2012 .

[76]  George Perry,et al.  Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. , 2010, Biochimica et biophysica acta.

[77]  Mark S. Shearman,et al.  Amyloid-β Hypothesis of Alzheimer’s Disease , 1998 .

[78]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .